ANDA 207742, held by Am Regent. Testosterone Cypionate.
As of Nov 16, 2026, ANDA 207742 (Testosterone Cypionate), held by Am Regent, was first approved by FDA on Jun 16, 2017, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Testosterone cypionate injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. 1. Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. Hypogonadotropic hypogonadism (congenital or acquired)-gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of testosterone cypionate injection in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 16, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Testosterone Cypionate200MG/ML · injectable;injection | Testosterone Cypionate | Rx |
| Jul 21, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jul 21, 2025 | Supplement 16Labeling · Standard review | Approved | None posted |
| Apr 4, 2018 | Supplement 1Manufacturing | Approved | None posted |
| Jun 16, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters